Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer By Ronald PianaNovember 25, 2019 In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India…
Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contribute to morbidity and mortality.This retrospective study describes treatment patterns and…
Blood Cancer Journal – Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contribute to morbidity and mortality.This retrospective study describes treatment patterns and…
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
Abstract. We used single-cell genomics to characterize a patient with T-cell acute lymphoblastic leukemia treated in the Children’s Oncology Group AALL0434
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
Leukemia – The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX-531 in combination with venetoclax (CPX + VEN) was tolerable and effective in…
Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX-531 in combination with venetoclax (CPX + VEN) was tolerable and effective in…
